{"prompt": "['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', 'The progress of the trial, safety issues and reports, including expedited reporting of SUSARs, will be', 'reported to the Competent Authority, regulatory agency or equivalent in accordance with relevant', 'national and local requirements and practices.', '6.3', 'Other approvals', 'The protocol will be submitted by those delegated to do so to the local departments of each', 'participating sites. A copy of the local approval letter (or other relevant approval as above) and of the', 'Participant Information Sheet (PIS) and consent form on local headed paper must be forwarded to', \"MeiraGTx UK Il Ltd. as part of the site initiation process prior to the site being designated 'open to\", \"recruitment' status.\", 'Participating sites receiving funding or support from the US government will obtain a Federal Wide', 'Assurance (FWA).', 'For ATIMP trials using Genetically Modified Organisms, organisations should also receive approval', 'from their relevant national body to use the product (i.e. notification to the HSE in the UK).', '6.4', 'Protocol Amendments', 'MeiraGTx UK II Ltd. will be responsible for amendments to the protocol. MeiraGTx UK II Ltd. will be', 'responsible for ensuring that protocol amendments are submitted to national competent authorities,', 'and to investigators at each clinical trial site.', 'Investigators at each clinical site will be responsible for submitting protocol amendments to the', 'relevant REC/IRBs for approval, as well as any additional competent authorities in each country that', 'require notification (e.g. the NIH OBA).', '6.5', 'Consent or Assent', 'The parents of potential participants will be provided with a Participant Information Sheet (PIS) and', 'given time to read it fully. Following a discussion with a medically qualified investigator or suitable', 'trained and authorised delegate, any questions will be satisfactorily answered and if the parent is', 'willing for their child to participate, written informed consent will be obtained. During the consent', 'process it will be made completely and unambiguously clear that the parent or guardian of a child is', 'free to refuse to participate in all or any aspect of the trial, at any time and for any reason, without', 'incurring any penalty or affecting the treatment of their child.', 'Children who are unable to consent for themselves will not be enrolled in the trial without the consent', 'of their parent(s) or legal guardian(s). Children or adolescents (aged 11-15) will be asked to assent or', 'agree. A Participant Information and Assent sheet that describes the details of the trial, trial', 'procedures, and risks in simplified form will be provided to children who have the capacity to provide', 'informed assent. Participation must be refused in the event that assent is not given. Assent forms do', \"not substitute for the consent form signed by the participant's legally authorized representative. If a\", 'child becomes an adult during their participation in the trial, the child will be reconsented as an adult', 'at the time of their next scheduled visit.', \"Consent will be re-sought if new information becomes available that affects the participant's consent\", 'in any way. This will be documented in a revision to the participant information sheet and the', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 59 of 68']['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', 'participant legally authorised representative will be asked to sign an updated consent form and assent', 'will be sought as appropriate. These will be approved by the appropriate ethics committee prior to', \"their use. Consent will also be re-sought in the event that a child's carer changes and when the child\", 'reaches the age of 16.', 'A copy of the approved consent and assent form are available from the MeiraGTx UK II Ltd. trial team.', '6.6 Confidentiality', 'All data will be handled in accordance with the General Data Protection Regulation 2016/679 and/or', 'the Health Insurance Portability and Accountability Act of 1996 (HIPAA).', 'These regulations require a signed participant authorization informing the participants of the', 'following:', 'What protected health information (PHI) will be collected from participants in this trial', 'Who will have access to that information and why', 'Who will use or disclose that information', 'The rights of a research participant to revoke their authorization for use of their PHI.', 'Where data will be held/stored', 'Rights that do not apply for research', 'How and why data is being used', 'In the event that a participant revokes authorization to collect or use PHI, the investigator, by', 'regulation, retains the ability to use all information collected prior to the revocation of participant', 'authorization. For participants that have revoked authorization to collect or use PHI, attempts should', 'be made to obtain permission to collect at least vital status (i.e. that the participant is alive) at the end', 'of their scheduled trial period.', 'Participant confidentiality will be held strictly in trust by the investigators, trial staff, and the sponsor', 'and their agents, to the extent provided by Federal, state, and local law. This confidentiality is', 'extended to cover testing of biological samples and genetic tests in addition to any trial information', 'relating to participants. All laboratory specimens, evaluation forms, reports, and other records that', 'leave the site will be identified only by a coded number in order to maintain participant confidentiality.', 'All records will be kept locked and all computer entry and networking programs will use coded', 'numbers only. Participants will not be identified in any publicly released reports of this trial.', 'Access to trial records will be limited to the minimum number of individuals necessary for quality', 'control, audit and analysis. Clinical information will not be released without written permission of the', 'participant, except as necessary for trial-related monitoring, audits, REC/IRB review, and regulatory', 'inspections by government entities. In these cases, the clinical trial site will provide direct access to all', 'source data, documents, and records maintained by the investigator, including but not limited to,', 'medical records (office, clinic, or hospital) for the trial participants. Trial participants will be informed', 'of this during the informed consent process.', 'No information concerning the trial, or the data will be released to any unauthorized third party', 'without prior written approval of MeiraGTx UK II Ltd.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 60 of 68']\n\n###\n\n", "completion": "END"}